Tuberculosis in recipients of solid-organ transplants during 1995–2015 in Cali, Colombia

José Fernado García-Goez, G. A. Munera, V. Rojas, R. Pacheco, J. A. Caylá, J. M. Miro

Research output: Contribution to journalArticlepeer-review


SETTING: Tuberculosis (TB) in solid-organ transplants (SOTs) is an important opportunistic infection associated with mortality and graft loss. SOT recipients carry a higher risk of contracting active TB than the general population. Clinical and radiographic presentations are non-specific, and sputum smear and culture have low yields. TB patients with SOTs require standard anti-tuberculosis treatment. However, rifampicin (RMP) use is associated with a 30% rate of acute graft rejection (AGR) and a 20% rate of transplant loss. OBJECTIVE: To determine treatment outcomes in SOT recipients with active TB. DESIGN: A retrospective study of clinical and microbiological data and TB treatment outcomes. RESULTS: Among the 2349 transplants assessed, active TB was detected in 31 recipients; 55% had pulmonary TB and 40% were sputum smear-positive. In 32% of the patients, TB was diagnosed 30 days after symptom onset, 77% of the patients were cured and 10% died. AGR occurred in 13%. CONCLUSION: TB was diagnosed in <30 days. Anti-tuberculosis treatment without RMP (80% vs. 67%; P = 0.48, OR 0.5, 95%CI 0.07–3.55) and with moxifloxacin yielded higher treatment success rates and a lower risk of AGR.

Original languageEnglish (US)
Pages (from-to)1155-1159+i
JournalInternational Journal of Tuberculosis and Lung Disease
Issue number11
StatePublished - Nov 1 2017


  • Moxifloxacin
  • Mycobacterium tuberculosis
  • Transplant rejection

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases


Dive into the research topics of 'Tuberculosis in recipients of solid-organ transplants during 1995–2015 in Cali, Colombia'. Together they form a unique fingerprint.

Cite this